Aerosol technology! Starco Brands launches hand wash spray
Recently, Starco Brands, a consumer products company based in California, USA, announced the launch of Breathe hand sanitizer, including three products that use "clean aerosol" dispensing technology.
Breathe is the company's first brand. At present, Breathe has become a household product brand, and its products are packaged in clean aerosol containers, including a furniture polish, a stainless steel polish, a bathroom cleaner and a multifunctional cleaner. Products are labeled with "industrial strength and non-toxic".
Starco Brands mainly uses compressed air as the propulsion force to fill products into aerosol packaging. The company stressed in a media press release issued this week that this continuous spray technology relies on "gas (mostly nitrogen, which accounts for 80% of human breathing air) as the propulsion power." This hand sanitizer formula contains an alcohol solution with a concentration of 75%. At the same time as it went on the market, the company also announced that it would apply for a patent for its spray technology.
Looking for chemical products? Let suppliers reach out to you!
2026-07-15
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
A Faster Route to Diabetes Drug Chemistry
-
Vertex Buys Crinetics for $10 Billion: Rare Disease M&A Is Back
-
Medicare’s $50 GLP-1 Door Opens: Weight-Loss Drug Demand Just Got Bigger
-
China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
-
FDA Fast-Tracks U.S. Drug Manufacturing
-
India’s Pharma Cost Problem Gets Worse
-
India Targets Fake Drug Packaging
-
FDA Warning Letters Put GMP Back in Focus
Recommend Reading
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Expected Short-term Peak Season Surge, This Week's Polyester Chip Market in China Shows High-level Fluctuations
-
China's Natural Rubber Prices First Decline Then Rise, Slightly Warming Up
-
ECHEMI 10th Anniversary
-
Firm Costs and Weak Demand Lead to High-Level Fluctuations in the Chinese PTA Market
-
When BASF Lets Agriculture Fly Solo: A Capital Repricing of Scale and Ambition